To report interim results of a TREM2 (triggering receptor expressed on myeloid cells 2) agonist from the first interventional study in ALSP.
No takes yet. Share an insight, caveat, or question.
Lynch et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: